3 ‘Strong Buy’ High-Risk/High-Reward Stocks to Bank on for 100%+ Upside Potential
Nektar Therapeutics ($NKTR), Applied Aerospace & Defense ($AADX), and T1 Energy ($TE) are three high-risk, high-reward stocks backed by Wall Street...
Nektar Therapeutics (NKTR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Seas Capital Sina Toussi | 3,345,978 | $202,582,238 | +9% | 2.33% |
| 2. | Iridian Asset Management David Cohen And Harold Levy | 94,697 | $5,733,430 | +145% | 2.09% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.28 | 15,000 | $259,200.00 | 107,668 | 2019-09-05 | Filing | |
| $59.80 | 1,400 | $83,720.00 | 177,000 | 2018-06-06 | Filing | |
| $59.07 | 2,000 | $118,140.00 | 175,600 | 2018-06-06 | Filing | |
| $55.22 | 1,600 | $88,352.00 | 173,600 | 2018-06-05 | Filing | |
| $17.95 | 35,000 | $628,250.00 | 133,000 | 2017-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $71.98 | 186 | $13,388.28 | 9,570 | 2026-08-18 | Filing | |
| $71.98 | 418 | $30,087.64 | 54,627 | 2026-08-18 | Filing | |
| $70.00 | 5,681 | $397,670.00 | 9,756 | 2026-06-30 | Filing | |
| $61.65 | 4,500 | $277,425.00 | 55,045 | 2026-06-17 | Filing | |
| $60.81 | 5,500 | $334,455.00 | 59,545 | 2026-06-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 58,902 | $3,566,222 | 0.68% | |
| 2. | 15,021 | $909,446 | 0.03% | |
| 3. | 9,930 | $601,212 | 0% | |
| 4. | 4,327 | $261,977 | 0% | |
| 5. | 4,000 | $242,180 | 0.01% |
News See All
Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang
Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here.
Nektar's (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development.
10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds
In this article, we will take a look at some of the best mid-cap healthcare stocks that are being highly favored by hedge funds.
Nektar Therapeutics (NASDAQ:NKTR) Q1 2026 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR) Q1 2026 Earnings Call Transcript May 8, 2026 Operator: Hello and thank you for standing by.
Bright Outlook for Nektar Therapeutics (NKTR) Hinges on Positive Trial Results
Michigan-based investment advisor Cedar Grove Capital Management recently released its first quarter 2026 investor letter. A copy of the letter can be downloaded here.
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript March 12, 2026Nektar Therapeutics beats earnings expectations. Reported EPS is $-1.77756, expectations were $-2.47411.
Nektar Therapeutics (NKTR): A Bull Case Theory
We came across a bullish thesis on Nektar Therapeutics on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NKTR.
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR)
With strong 1-year returns and upside potential, Nektar Therapeutics (NASDAQ:NKTR) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.
12 Best Multibagger Stocks to Buy Heading into 2026
In this article, we discuss the 12 Best Multibagger Stocks to Buy Heading into 2026.
Hedge Fund Resource Center